KPWHRI psychologist and researcher Ben Balderson, PhD, shares advice for keeping our spirits up during this most unusual holiday season.
The investigational vaccine that KPWHRI’s team first tested shows an efficacy rate of 94.5% as Phase 3 research continues.
The institute is participating in NIAID tests of Moderna and Johnson & Johnson vaccines.
The investigational mRNA vaccine is also well tolerated, according to trial led by Kaiser Permanente Washington researcher and others.
Can lessons from Immunity Community help build acceptance of COVID-19 vaccines? Clarissa Hsu, PhD, thinks so.
How Paula Blasi brings research findings to light to support Kaiser Permanente’s rapid response to COVID-19
Dr. Eric B. Larson, a report contributor, answers questions about reducing risks, disparities, and threats from COVID-19.